Non-peptide

Aleniglipron

Also known as

GSBR-1290 · Structure Therapeutics oral GLP-1 · aleniglipron pill

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	GSBR-1290, an experimental oral small-molecule GLP-1 drug for weight management.
Why people discuss it	A daily pill without injections appeals to some; others prefer fewer doses to remembering another tablet.

Notes

Aleniglipron, also called GSBR-1290, is an experimental GLP-1 pill for weight management. People discuss losing weight without injections, easier daily routines and potentially lower costs. The conversation is mainly about trials and future options; it does not establish how taking Aleniglipron personally feels.

A small molecule, rather than a peptide. It activates the GLP-1 receptor, part of the body's appetite and glucose-control system. This oral compound is distinct from semaglutide tablets such as Rybelsus and from injected tirzepatide. Different drugs' milligram amounts and absorption rules are not interchangeable. September 8 ACCESS extension and Phase 3 update (Official context · Accessed 2026-09-30)

Weight management without the injection hurdle. Mounjaro-community replies welcome a pill for needle-averse people. One hopes to move from injections to tablets after reaching a goal weight. That is a maintenance wish, not a successful Aleniglipron switch report. Structure's Aleniglipron GLP-1 pill: Mounjaro-community replies (Community discussion · Accessed 2026-09-30)

Needle-free does not automatically mean easier to remember. One Mounjaro commenter prefers their existing treatment because they forget tablets; another already uses a weekly pill organizer. A separate June reply prefers a weekly or monthly shot to another daily pill. These are practical preferences, not failed Aleniglipron treatments. Structure's Aleniglipron GLP-1 pill: Mounjaro-community replies (Community discussion · Accessed 2026-09-30) · Another oral GLP-1 pill is moving through clinical trials (Community discussion · Accessed 2026-09-30)

Source context — September 8 ACCESS extension and Phase 3 update: Commercial sponsor extension topline and forward-looking status; not controlled 72-week placebo comparison or community onset/duration evidence. Sponsor investor-domain and gcs-web copies are one original. ACCG-2671 is a separate molecule.

Source context — Structure's Aleniglipron GLP-1 pill: Mounjaro-community replies: News-sharing discussion, not Aleniglipron use. OP republishes news based on sponsor findings; numerical claims keep ACCESS II as their actual origin. Replies support pill adherence, needle avoidance, cost hopes and maintenance wishes only; no prevalence estimate.

Source context — Another oral GLP-1 pill is moving through clinical trials: Pipeline opinions and expectations; not personal Aleniglipron outcomes or proof of lower prices. June phase-2 status is historical; current status comes from the September sponsor update.

What people notice

Personal experience	The saved discussions cover trials and future options, rather than timed firsthand Aleniglipron experiences. Quieter appetite reports borrowed from other GLP-1 drugs are not its own diary record.
Trial weight change	ACCESS II reported 16.3% placebo-adjusted weight loss at 180 mg and 16.0% at 240 mg after 44 weeks. These are trial group results.
Convenience and cost	People hope for simpler routines and lower prices; the discussions do not establish a successful switch or a consumer saving.

Notes

Appetite relief is a goal, not a verified diary here. The existing community record includes quieter appetite, early nausea and difficulty eating enough protein borrowed from other oral GLP-1 discussions. Those experiences explain the questions people bring to this pill; they do not establish Aleniglipron's individual response pattern.

ACCESS and ACCESS II are separate trials. ACCESS daily targets were 45, 90 and 120 mg: 11.3% placebo-adjusted weight loss at 120 mg after 36 weeks. ACCESS II: 16.3% at 180 mg and 16.0% at 240 mg after 44 weeks. These are group results. ACCESS original phase 2b trial (Official context · Accessed 2026-09-30) · March 2026 ACCESS II results and lower-start context (Official context · Accessed 2026-09-30)

Price and everyday convenience matter too. People hope simpler manufacturing, shipping and storage will lower prices. That is an expectation, not an established consumer price or demonstrated saving. Structure's Aleniglipron GLP-1 pill: Mounjaro-community replies (Community discussion · Accessed 2026-09-30)

Source context — ACCESS original phase 2b trial: Formal randomized human trial, not a community diary. ACCESS is distinct from ACCESS II. Table 2 reports cumulative events, not acute response probabilities. Sponsor-supported research with selected eligibility; exclusions do not establish safety in excluded populations.

Source context — March 2026 ACCESS II results and lower-start context: Commercial sponsor topline/interim disclosure; release and same-day deck counted as one source family. Lower-start cohorts are not a randomized start-dose comparison. Later-dose selected subgroup cannot stand for all participants.

Doses people talk about

ACCESS II targets	120, 180 and 240 mg orally once daily after trial titration. These are study targets, not community starting amounts.
Other study amounts	ACCESS tested daily targets of 45, 90 and 120 mg. A 20 mg step belonged to a separate capsule-to-tablet study.
Lower-start cohorts	Later cohorts began at 2.5 mg daily for four weeks, versus earlier 5 mg starts. Separate cohorts cannot show that the starting amount alone improved tolerance.

Notes

Oral, once daily; 120, 180 and 240 mg are circulated trial targets. The March discussion repeats ACCESS II amounts, reached after gradual increases. They are study target amounts per daily administration, not a community-tested range, starting amounts or a consumer label. Structure's Aleniglipron GLP-1 pill: Mounjaro-community replies (Community discussion · Accessed 2026-09-30) · Another oral GLP-1 pill is moving through clinical trials (Community discussion · Accessed 2026-09-30)

Starts differ from study steps and targets. Later cohorts began at 2.5 mg daily for four weeks; earlier cohorts at 5 mg. The capsule-to-tablet study included a 20 mg step. These are trial regimens. March 2026 ACCESS II results and lower-start context (Official context · Accessed 2026-09-30) · June 2024 capsule-to-tablet sponsor presentation (Official context · Accessed 2026-09-30)

2.5 mg is discussed as a lower trial starting amount. An investor reply links improved tolerability to a separate study extension using that start. This repeats sponsor data; it does not establish a personal progression, or prove that changing the starting amount alone caused better tolerance. Structure therapeutics PII oral pill success: tolerability disagreement (Community discussion · Accessed 2026-09-30)

Source context — June 2024 capsule-to-tablet sponsor presentation: Sponsor human plasma measurements, not community experience. Capsule late sampling limits noted. The animal-derived concentration threshold on the same slide is not adopted as a human felt threshold.

Source context — Structure therapeutics PII oral pill success: tolerability disagreement: Investment forum with financial incentives, secondhand trial claims and cross-trial assertions; not Aleniglipron users. Lower-start claim cites sponsor disclosure and stays sponsor-origin. No-discontinuation interim claim is not represented as current or whole-study safety.

Half-life, onset & duration

Felt onset	Not established in the saved Aleniglipron discussions; other GLP-1 users' first-week experiences do not supply it.
Felt duration	No reliable single-tablet appetite window is described. Daily study dosing does not prove all-day effects.
Half-life	Sponsor human measurements: 8.5 hours for 120 mg tablets, 4.7 hours for 60 mg tablets and 6.5 hours for 60 mg capsules. The 120 mg capsule estimate of 5.3 hours may be underestimated by short sampling.

Notes

A dependable first-dose or first-week onset is unknown here. The opened Aleniglipron threads discuss results and convenience, not timed personal responses. Other GLP-1 users' week-one nausea or appetite changes cannot supply this compound's onset.

No reliable felt window after one tablet. A daily study regimen and weight-loss headlines measured over months do not show whether appetite effects last all day, fade before the next dose or persist after stopping. The checked threads provide no clean personal offset account. Mounjaro might have real competition by 2028: corrections and methods debate (Community discussion · Accessed 2026-09-30)

Human half-life measurements depend on the formulation. The 2024 sponsor table gives 8.5 hours for 120 mg tablets, 4.7 hours for 60 mg tablets and 6.5 hours for 60 mg capsules. The 120 mg capsule estimate was 5.3 hours, possibly underestimated by sampling ending at 24 hours. These measure a fall in blood concentration, not felt duration. June 2024 capsule-to-tablet sponsor presentation (Official context · Accessed 2026-09-30)

Source context — Mounjaro might have real competition by 2028: corrections and methods debate: Opening confuses drug identity; plateau claim conflates ACCESS II with ACCESS OLE. Liver-taxing comment is unsupported speculation. Adopt questions and convenience expectations, not those errors or predicted approval timing.

Cycles people discuss

Maintenance interest	People discuss long-term maintenance, without an established weeks-on/off calendar. Trial follow-up lengths are not community cycles.

Notes

Long-term maintenance interest, without a reported cycling calendar. Maintenance wishes are not cycling reports. No inspected account establishes weeks on, weeks off, repeat courses or a safe break. Trial follow-up lengths are not bodybuilding cycles. Structure's Aleniglipron GLP-1 pill: Mounjaro-community replies (Community discussion · Accessed 2026-09-30)

Stacks

Combinations	The saved discussion compares other GLP-1 drugs rather than describing an Aleniglipron combination. ACCESS restricted other weight-loss medicines.

Notes

Comparisons in discussion: Orforglipron, Rybelsus, injected semaglutide and tirzepatide are alternatives people compare, not a reported Aleniglipron combination. [community]

Pregnancy, other medicines and combinations remain important unknowns. ACCESS excluded pregnancy and breastfeeding and restricted interacting medicines and other weight-loss drugs. Its findings do not establish safety in these situations, in GLP-1 stacks or over many years. ACCESS original phase 2b trial (Official context · Accessed 2026-09-30)

Watch for

Nausea and vomiting	These occurred in ACCESS and some participants stopped. Later improvement in group symptoms does not guarantee tolerance; inability to keep fluids down needs medical assessment.
Study comparisons	ACCESS and ACCESS II have different participants and stopping-rate denominators. Their percentages cannot be treated as one study or a head-to-head comparison with another drug.
Unresolved safety	Pregnancy, breastfeeding, combinations and long-term safety are not established by these trials. Aleniglipron remains investigational in the saved record.

Notes

A pill can still cause nausea and vomiting. ACCESS stomach and bowel symptoms generally decreased later, but some participants stopped. Continuing does not guarantee tolerance. Inability to keep food or fluids down needs medical assessment. ACCESS original phase 2b trial (Official context · Accessed 2026-09-30)

Vomiting and stopping have different denominators. ACCESS vomiting: 40.0%, 44.6% and 31.7% at 45, 90 and 120 mg; placebo 5.4%, over 36 weeks. Treatment-related discontinuation: 10.4%, versus ACCESS II's 3.7%—one of 27 re-randomized participants in weeks 28–44. ACCESS original phase 2b trial (Official context · Accessed 2026-09-30) · March 2026 ACCESS II results and lower-start context (Official context · Accessed 2026-09-30)

A larger weight-loss headline does not settle the comparison. Pipeline replies question dose size, slow increases and how diet and exercise differed between trials. One correction identifies Aleniglipron after the opening post names another drug. The same discussion mixes study timelines; it cannot prove a plateau or superiority over orforglipron, semaglutide or tirzepatide. Mounjaro might have real competition by 2028: corrections and methods debate (Community discussion · Accessed 2026-09-30)

Later results extend the follow-up, not personal certainty. The September 8 sponsor update reports up to 16.2% weight loss from baseline through 72 weeks in the ACCESS extension, with escalation to 180 mg after week 60. Phase 3 is underway; approval remains unresolved. The release's six-day half-life belongs to ACCG-2671, a different compound. September 8 ACCESS extension and Phase 3 update (Official context · Accessed 2026-09-30)

These observations do not guarantee future safety. March reported no drug-induced liver injury or prolonged QTc, the heart's electrical recovery interval. September's liver-enzyme elevations resolved without liver injury. These are bounded sponsor observations. March 2026 ACCESS II results and lower-start context (Official context · Accessed 2026-09-30) · September 8 ACCESS extension and Phase 3 update (Official context · Accessed 2026-09-30)

Full notes

A GLP-1 pill with its own identity

A small molecule, rather than a peptide. It activates the GLP-1 receptor, part of the body's appetite and glucose-control system. This oral compound is distinct from semaglutide tablets such as Rybelsus and from injected tirzepatide. Different drugs' milligram amounts and absorption rules are not interchangeable. Official context Community
A simpler daily routine is part of the appeal. Pipeline posters hope a pill will reduce fasting restrictions and refrigeration needs. These are convenience expectations, not universal storage instructions. Aleniglipron remains investigational; future packaging and approved directions cannot be inferred from a forum post or a product marketed as an oral GLP-1 powder. Reddit · r/GLP1ResearchTalk Community

What people hope to gain

Weight management without the injection hurdle. Mounjaro-community replies welcome a pill for needle-averse people. One hopes to move from injections to tablets after reaching a goal weight. That is a maintenance wish, not a successful Aleniglipron switch report. Reddit · r/mounjarouk
Price and everyday convenience matter too. People hope simpler manufacturing, shipping and storage will lower prices. That is an expectation, not an established consumer price or demonstrated saving. Reddit · r/mounjarouk
Appetite relief is a goal, not a verified diary here. The existing community record includes quieter appetite, early nausea and difficulty eating enough protein borrowed from other oral GLP-1 discussions. Those experiences explain the questions people bring to this pill; they do not establish Aleniglipron's individual response pattern. Community

Doses people discuss

Oral, once daily; 120, 180 and 240 mg are circulated trial targets. The March discussion repeats ACCESS II amounts, reached after gradual increases. They are study target amounts per daily administration, not a community-tested range, starting amounts or a consumer label. Reddit · r/mounjarouk Reddit · r/GLP1ResearchTalk
2.5 mg is discussed as a lower trial starting amount. An investor reply links improved tolerability to a separate study extension using that start. This repeats sponsor data; it does not establish a personal progression, or prove that changing the starting amount alone caused better tolerance. Reddit · r/NovoNordisk_Stock

Half-life

No independently established community estimate in these discussions. Daily-pill talk does not measure how quickly the compound leaves the body. Human laboratory measurements are described separately below; they are not community measurements or an appetite clock. Reddit · r/NovoNordisk_Stock

Onset: when a change is noticed

A dependable first-dose or first-week onset is unknown here. The opened Aleniglipron threads discuss results and convenience, not timed personal responses. Other GLP-1 users' week-one nausea or appetite changes cannot supply this compound's onset. Community

Duration: how long an effect lasts

No reliable felt window after one tablet. A daily study regimen and weight-loss headlines measured over months do not show whether appetite effects last all day, fade before the next dose or persist after stopping. The checked threads provide no clean personal offset account. Reddit · r/GLP1ResearchTalk

Cycles and time off

Long-term maintenance interest, without a reported cycling calendar. Maintenance wishes are not cycling reports. No inspected account establishes weeks on, weeks off, repeat courses or a safe break. Trial follow-up lengths are not bodybuilding cycles. Reddit · r/mounjarouk

What deserves caution

A pill can still cause nausea and vomiting. ACCESS stomach and bowel symptoms generally decreased later, but some participants stopped. Continuing does not guarantee tolerance. Inability to keep food or fluids down needs medical assessment. Official context Community
Pregnancy, other medicines and combinations remain important unknowns. ACCESS excluded pregnancy and breastfeeding and restricted interacting medicines and other weight-loss drugs. Its findings do not establish safety in these situations, in GLP-1 stacks or over many years. Official context

The useful disagreements in community discussion

Needle-free does not automatically mean easier to remember. One Mounjaro commenter prefers their existing treatment because they forget tablets; another already uses a weekly pill organizer. A separate June reply prefers a weekly or monthly shot to another daily pill. These are practical preferences, not failed Aleniglipron treatments. Reddit · r/mounjarouk Reddit · r/GLP1ResearchTalk
Tolerability divides even enthusiastic investors. The stock-community thread contains excitement about weight loss, concern about vomiting, questions about how many stopped and optimism about lower starting amounts. Later replies remain critical of side effects and retention. This is debate about trial disclosures, not multiple firsthand adverse accounts or proof that staying on treatment resolves symptoms. Reddit · r/NovoNordisk_Stock
A larger weight-loss headline does not settle the comparison. Pipeline replies question dose size, slow increases and how diet and exercise differed between trials. One correction identifies Aleniglipron after the opening post names another drug. The same discussion mixes study timelines; it cannot prove a plateau or superiority over orforglipron, semaglutide or tirzepatide. Reddit · r/GLP1ResearchTalk

Study context behind the circulated numbers

ACCESS and ACCESS II are separate trials. ACCESS daily targets were 45, 90 and 120 mg: 11.3% placebo-adjusted weight loss at 120 mg after 36 weeks. ACCESS II: 16.3% at 180 mg and 16.0% at 240 mg after 44 weeks. These are group results. Official context Official context
Starts differ from study steps and targets. Later cohorts began at 2.5 mg daily for four weeks; earlier cohorts at 5 mg. The capsule-to-tablet study included a 20 mg step. These are trial regimens. Official context Official context
Human half-life measurements depend on the formulation. The 2024 sponsor table gives 8.5 hours for 120 mg tablets, 4.7 hours for 60 mg tablets and 6.5 hours for 60 mg capsules. The 120 mg capsule estimate was 5.3 hours, possibly underestimated by sampling ending at 24 hours. These measure a fall in blood concentration, not felt duration. Official context
Vomiting and stopping have different denominators. ACCESS vomiting: 40.0%, 44.6% and 31.7% at 45, 90 and 120 mg; placebo 5.4%, over 36 weeks. Treatment-related discontinuation: 10.4%, versus ACCESS II's 3.7%—one of 27 re-randomized participants in weeks 28–44. Official context Official context
Later results extend the follow-up, not personal certainty. The September 8 sponsor update reports up to 16.2% weight loss from baseline through 72 weeks in the ACCESS extension, with escalation to 180 mg after week 60. Phase 3 is underway; approval remains unresolved. The release's six-day half-life belongs to ACCG-2671, a different compound. Official context
These observations do not guarantee future safety. March reported no drug-induced liver injury or prolonged QTc, the heart's electrical recovery interval. September's liver-enzyme elevations resolved without liver injury. These are bounded sponsor observations. Official context Official context